Xiao-Jian Zhou, Ph.D.

EVP, Early Stage Development
Atea Pharmaceuticals, Inc.

Disclosure: Atea Pharmaceuticals, Inc. (Individual(s) Involved: Self): Employee

Presentation(s):

• 169 - AT-752, an Oral Guanosine Nucleotide Prodrug, Exhibits Potent in Vitro Activity Against Flaviviruses and Prevents Disease Progression in a Dengue Mouse Model

  Oral Abstract